Kalipso Chalkidou

Summary

Affiliation: National Institute for Health and Clinical Excellence
Country: UK

Publications

  1. doi request reprint Evidence-based decision making: when should we wait for more information?
    Kalipso Chalkidou
    Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, USA
    Health Aff (Millwood) 27:1642-53. 2008
  2. doi request reprint Interview: Setting up NICE International
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence International, MidCity Place, 71 High Holborn, London, UK
    J Comp Eff Res 1:121-4. 2012
  3. doi request reprint Evidence and values: paying for end-of-life drugs in the British NHS
    Kalipso Chalkidou
    NICE International, London, UK
    Health Econ Policy Law 7:393-409. 2012
  4. doi request reprint The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence, London, UK
    Clin Trials 9:436-46. 2012
  5. doi request reprint Pharmacogenetics and cost-effectiveness analysis: a two-way street
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence, UK
    Drug Discov Today 16:873-7. 2011
  6. doi request reprint Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care
    Kalipso Chalkidou
    NICE International, National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London, WC1V 6NA, UK
    Int J Technol Assess Health Care 27:151-8. 2011
  7. doi request reprint Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future
    Kalipso Chalkidou
    NICE International, National Institute for Health and Clinical Excellence, London, UK
    Pharmacoeconomics 28:799-811. 2010
  8. doi request reprint Eliminating drug price differentials across government programmes in the USA
    Kalipso Chalkidou
    NICE International, National Institute for Health and Clinical Excellence, London, UK
    Health Econ Policy Law 6:43-64. 2011
  9. ncbi request reprint Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence
    Issue Brief (Commonw Fund) 59:1-12. 2009
  10. doi request reprint Comparative effectiveness research priorities: identifying critical gaps in evidence for clinical and health policy decision making
    Kalipso Chalkidou
    National Institute of Health and Clinical Excellence, 71 High Holborn, London WC1V 6NA, UK
    Int J Technol Assess Health Care 25:241-8. 2009

Detail Information

Publications23

  1. doi request reprint Evidence-based decision making: when should we wait for more information?
    Kalipso Chalkidou
    Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, USA
    Health Aff (Millwood) 27:1642-53. 2008
    ..We conclude that there is a need for better integration of health care decision-making processes with research policies...
  2. doi request reprint Interview: Setting up NICE International
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence International, MidCity Place, 71 High Holborn, London, UK
    J Comp Eff Res 1:121-4. 2012
    b>Kalipso Chalkidou is the founding director of the NICE's international program helping governments build technical and institutional capacity for using evidence to inform health policy...
  3. doi request reprint Evidence and values: paying for end-of-life drugs in the British NHS
    Kalipso Chalkidou
    NICE International, London, UK
    Health Econ Policy Law 7:393-409. 2012
    ....
  4. doi request reprint The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence, London, UK
    Clin Trials 9:436-46. 2012
    ..While the level of interest and activity in conducting pRCTs is increasing, many challenges remain for their routine use. This article discusses those challenges and offers some potential ways forward...
  5. doi request reprint Pharmacogenetics and cost-effectiveness analysis: a two-way street
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence, UK
    Drug Discov Today 16:873-7. 2011
    ....
  6. doi request reprint Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care
    Kalipso Chalkidou
    NICE International, National Institute for Health and Clinical Excellence, MidCity Place, 71 High Holborn, London, WC1V 6NA, UK
    Int J Technol Assess Health Care 27:151-8. 2011
    ....
  7. doi request reprint Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future
    Kalipso Chalkidou
    NICE International, National Institute for Health and Clinical Excellence, London, UK
    Pharmacoeconomics 28:799-811. 2010
    ..We draw some possible lessons for the US, which is currently considering using CER to inform healthcare policy and practice decisions...
  8. doi request reprint Eliminating drug price differentials across government programmes in the USA
    Kalipso Chalkidou
    NICE International, National Institute for Health and Clinical Excellence, London, UK
    Health Econ Policy Law 6:43-64. 2011
    ....
  9. ncbi request reprint Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence
    Issue Brief (Commonw Fund) 59:1-12. 2009
    ..NICE committees consider comparative clinical and cost effectiveness, social values (including impact on equity), and U.K. and European Union legislation when making their decisions...
  10. doi request reprint Comparative effectiveness research priorities: identifying critical gaps in evidence for clinical and health policy decision making
    Kalipso Chalkidou
    National Institute of Health and Clinical Excellence, 71 High Holborn, London WC1V 6NA, UK
    Int J Technol Assess Health Care 25:241-8. 2009
    ..However, how such a function, in terms of methods and process, would go about identifying the most important priorities warranting further research has received little attention...
  11. ncbi request reprint Cost-effective public health guidance: asking questions from the decision-maker's viewpoint
    Kalipso Chalkidou
    Research and Development, National Institute for Health and Clinical Excellence, London, UK
    Health Econ 17:441-8. 2008
    ....
  12. pmc Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research
    Kalipso Chalkidou
    Associate Director, Research and Development, National Institute for Health and Clinical Excellence, 71 High Holborn, WC1V 6NA, London, UK
    J R Soc Med 100:453-60. 2007
  13. doi request reprint The (possible) impact of comparative effectiveness research on pharmaceutical industry decision making
    K Chalkidou
    NICE International, London, UK
    Clin Pharmacol Ther 87:264-6. 2010
    ..For health-care systems in developed and developing countries around the world, faced with limited budgets, there may be no third option...
  14. doi request reprint Evidence-informed evidence-making
    Kalipso Chalkidou
    Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Health Serv Res Policy 13:167-73. 2008
    ..We propose ways in which NICE can collaborate more effectively with research funders to improve the evidence base upon which it bases its recommendations...
  15. pmc Comparative effectiveness research and evidence-based health policy: experience from four countries
    Kalipso Chalkidou
    National Institute for Health and Clinical Excellence, London, UK
    Milbank Q 87:339-67. 2009
    ..This article reviews experiences from Britain, France, Australia, and Germany...
  16. pmc Sharing the British National Health Service around the world: a self-interested perspective
    Kalipso Chalkidou
    NICE International, National Institute for Health and Clinical Excellence, 10 Spring Gardens, SW1A 2BU London, UK
    Global Health 9:51. 2013
    ....
  17. pmc Expensive cancer drugs: a comparison between the United States and the United Kingdom
    Ruth R Faden
    Johns Hopkins University, Baltimore, MD 21205, USA
    Milbank Q 87:789-819. 2009
    ..This article compares the United Kingdom's and the United States' experiences with expensive cancer drugs to illustrate the challenges posed by new, extremely costly, medical technologies...
  18. doi request reprint Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries
    Kalipso Chalkidou
    NICE International, London, UK Electronic address
    Lancet Oncol 15:e119-31. 2014
    ....
  19. doi request reprint Reflections on the evolution of health technology assessment in Europe
    Corinna Sorenson
    Research Fellow in Health Policy, London School of Economics, London, UK
    Health Econ Policy Law 7:25-45. 2012
    ....
  20. pmc Priority-setting for achieving universal health coverage
    Kalipso Chalkidou
    NICE International, London, England
    Bull World Health Organ 94:462-7. 2016
    ..We provide justification for explicit health priority-setting and guidance to countries on how to set priorities for UHC. ..
  21. doi request reprint Public participation in decision-making on the coverage of new antivirals for hepatitis C
    Katharina Kieslich
    Department of Primary Care and Public Health Sciences, King s College London, London, UK
    J Health Organ Manag 30:769-85. 2016
    ..Public participation activities can thus contribute to setting policy agendas, even if that is not their explicit purpose. However, the actualization of this contribution is contingent on the receptiveness of policymakers. ..
  22. ncbi request reprint Coverage with evidence development: a very good beginning, but much to be done. Commentary to Hutton et al
    Sean R Tunis
    Centre for Medical Technology Policy, 524 2nd Street, San Francisco, California 94107, USA
    Int J Technol Assess Health Care 23:432-5. 2007
  23. pmc How to formulate research recommendations
    Polly Brown
    BMJ Publishing Group, London WC1H 9JR
    BMJ 333:804-6. 2006